» Articles » PMID: 38153537

Hexahydrocurcumin Attenuated Demyelination and Improved Cognitive Impairment in Chronic Cerebral Hypoperfusion Rats

Overview
Specialty Pharmacology
Date 2023 Dec 28
PMID 38153537
Authors
Affiliations
Soon will be listed here.
Abstract

Age-related white matter lesions (WML) frequently present vascular problems by decreasing cerebral blood supply, resulting in the condition known as chronic cerebral hypoperfusion (CCH). This study aimed to investigate the effect of hexahydrocurcumin (HHC) on the processes of demyelination and remyelination induced by the model of the Bilateral Common Carotid Artery Occlusion (BCCAO) for 29 days to mimic the CCH condition. The pathological appearance of myelin integrity was significantly altered by CCH, as evidenced by Transmission Electron Microscopy (TEM) and Luxol Fast Blue (LFB) staining. In addition, CCH activated A1-astrocytes and reactive-microglia by increasing the expression of Glial fibrillary acidic protein (GFAP), complement 3 (C3d) and pro-inflammatory cytokines. However, S100a10 expression, a marker of neuroprotective astrocytes, was suppressed, as were regenerative factors including (IGF-1) and Transglutaminase 2 (TGM2). Therefore, the maturation step was obstructed as shown by decreases in the levels of myelin basic protein (MBP) and the proteins related with lipid synthesis. Cognitive function was therefore impaired in the CCH model, as evidenced by the Morris water maze test. By contrast, HHC treatment significantly improved myelin integrity, and inhibited A1-astrocytes and reactive-microglial activity. Consequently, pro-inflammatory cytokines and A1-astrocytes were attenuated, and regenerative factors increased assisting myelin maturation and hence improving cognitive performance. In conclusion, HHC improves cognitive function and also the integrity of white matter in CCH rats by reducing demyelination, and pro-inflammatory cytokine production and promoting the process of remyelination.

Citing Articles

Toll-Like Receptor 4-Mediated Neuroinflammation: Updates on Pathological Roles and Therapeutic Strategies in Chronic Cerebral Hypoperfusion.

Yawoot N, Tocharus J, Tocharus C Mol Neurobiol. 2025; .

PMID: 39875782 DOI: 10.1007/s12035-025-04718-7.


Comparative Pharmacokinetics and Tissue Distribution of Hexahydrocurcumin Following Intraperitoneal vs Oral Administration in Mice Using LC-MS/MS.

Chaiyasaeng W, Hongwiset D, Tocharus C, Punyawudho B, Tocharus J, Chaichompoo W ACS Omega. 2024; 9(39):41032-41042.

PMID: 39372019 PMC: 11447725. DOI: 10.1021/acsomega.4c06604.


Proteomic Profile of Circulating Extracellular Vesicles in the Brain after Δ9-Tetrahydrocannabinol Inhalation.

Lallai V, Lam T, Garcia-Milian R, Chen Y, Fowler J, Manca L Biomolecules. 2024; 14(9).

PMID: 39334909 PMC: 11430348. DOI: 10.3390/biom14091143.

References
1.
Akiguchi I, Tomimoto H, Suenaga T, Wakita H, Budka H . Alterations in glia and axons in the brains of Binswanger's disease patients. Stroke. 1997; 28(7):1423-9. DOI: 10.1161/01.str.28.7.1423. View

2.
Anand P, Thomas S, Kunnumakkara A, Sundaram C, Harikumar K, Sung B . Biological activities of curcumin and its analogues (Congeners) made by man and Mother Nature. Biochem Pharmacol. 2008; 76(11):1590-611. DOI: 10.1016/j.bcp.2008.08.008. View

3.
Baaklini C, Rawji K, Duncan G, Ho M, Plemel J . Central Nervous System Remyelination: Roles of Glia and Innate Immune Cells. Front Mol Neurosci. 2019; 12:225. PMC: 6764409. DOI: 10.3389/fnmol.2019.00225. View

4.
Behrendt G, Baer K, Buffo A, Curtis M, Faull R, Rees M . Dynamic changes in myelin aberrations and oligodendrocyte generation in chronic amyloidosis in mice and men. Glia. 2012; 61(2):273-86. DOI: 10.1002/glia.22432. View

5.
Chida Y, Kokubo Y, Sato S, Kuge A, Takemura S, Kondo R . The alterations of oligodendrocyte, myelin in corpus callosum, and cognitive dysfunction following chronic cerebral ischemia in rats. Brain Res. 2011; 1414:22-31. DOI: 10.1016/j.brainres.2011.07.026. View